Literature DB >> 28283702

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Wolfgang P Fendler1,2, Matthias Eiber1,3, Mohsen Beheshti4, Jamshed Bomanji5, Francesco Ceci6, Steven Cho7, Frederik Giesel8, Uwe Haberkorn8, Thomas A Hope9, Klaus Kopka10, Bernd J Krause11, Felix M Mottaghy12,13, Heiko Schöder14, John Sunderland15, Simon Wan5, Hans-Jürgen Wester16, Stefano Fanti6, Ken Herrmann17,18.   

Abstract

The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of 68Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.

Entities:  

Keywords:  Guideline; PET; PSMA; Prostate cancer; Restaging; Staging

Mesh：

Substances：

Year:  2017        PMID： 28283702     DOI： 10.1007/s00259-017-3670-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  52 in total

1.  Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Authors:  Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes
Journal:  Pathol Oncol Res       Date:  2008-09-18       Impact factor: 3.201

2.  Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.

Authors:  Kambiz Rahbar; Matthias Schmidt; Alexander Heinzel; Elisabeth Eppard; Axel Bode; Anna Yordanova; Michael Claesener; Hojjat Ahmadzadehfar
Journal:  J Nucl Med       Date:  2016-04-07       Impact factor: 10.057

3.  Acceptance testing for nuclear medicine instrumentation.

Authors:  Ellinor Busemann Sokole; Anna Płachcínska; Alan Britten
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03       Impact factor: 9.236

4.  68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.

Authors:  Hojjat Ahmadzadehfar; Carl Diedrich Schlenkhoff; Sebastian Rogenhofer; Anna Yordanova; Markus Essler
Journal:  Clin Nucl Med       Date:  2016-09       Impact factor: 7.794

5.  (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors:  Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-23       Impact factor: 9.236

6.  Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3.

Authors:  Piotr Laidler; Joanna Dulińska; Małgorzata Lekka; Janusz Lekki
Journal:  Arch Biochem Biophys       Date:  2005-03-01       Impact factor: 4.013

7.  Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.

Authors:  Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

8.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

Authors:  Martina Benešová; Martin Schäfer; Ulrike Bauder-Wüst; Ali Afshar-Oromieh; Clemens Kratochwil; Walter Mier; Uwe Haberkorn; Klaus Kopka; Matthias Eder
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

Review 9.  Neuroendocrine differentiation of prostate cancer: a review.

Authors:  Vamsi Parimi; Rajen Goyal; Kate Poropatich; Ximing J Yang
Journal:  Am J Clin Exp Urol       Date:  2014-12-09

10.  Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.

Authors:  Ali Afshar-Oromieh; Henrik Hetzheim; Wolfgang Kübler; Clemens Kratochwil; Frederik L Giesel; Thomas A Hope; Matthias Eder; Michael Eisenhut; Klaus Kopka; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-03       Impact factor: 9.236
View more
  195 in total

1.  False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography.

Authors:  Sofiullah Olayinka Abubakar; Yaw Ampem Amoako; Naima Tag; Tessa Kotze
Journal:  World J Nucl Med       Date:  2018 Oct-Dec

2.  [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.

Authors:  Mark A Green; Gary D Hutchins; Clinton D Bahler; Mark Tann; Carla J Mathias; Wendy Territo; Justin Sims; Heather Polson; David Alexoff; William C Eckelman; Hank F Kung; James W Fletcher
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

3.  Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Authors:  Jeremie Calais; Amar U Kishan; Minsong Cao; Wolfgang P Fendler; Matthias Eiber; Ken Herrmann; Francesco Ceci; Robert E Reiter; Matthew B Rettig; John V Hegde; Narek Shaverdian; Chris R King; Michael L Steinberg; Johannes Czernin; Nicholas G Nickols
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

4.  Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis.

Authors:  Alex Zwanenburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-25       Impact factor: 9.236

5.  Novel Structured Reporting Systems for Theranostic Radiotracers.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Stefano Fanti; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Ken Herrmann; Constantin Lapa; Steven P Rowe
Journal:  J Nucl Med       Date:  2019-02-22       Impact factor: 10.057

6.  68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Authors:  Christos Sachpekidis; Leyun Pan; Boris A Hadaschik; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

7.  Intraoperative 68Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study.

Authors:  Christopher Darr; Nina N Harke; Jan Philipp Radtke; Leubet Yirga; Claudia Kesch; Maarten R Grootendorst; Wolfgang P Fendler; Pedro Fragoso Costa; Christoph Rischpler; Christine Praus; Johannes Haubold; Henning Reis; Thomas Hager; Ken Herrmann; Ina Binse; Boris Hadaschik
Journal:  J Nucl Med       Date:  2020-02-14       Impact factor: 10.057

8.  Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction.

Authors:  Julian Müller; Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Sarah Kedzia; Daniel Eberli; Matthias Guckenberger; Stephanie G C Kroeze; Tullio Sulser; Daniel M Schmid; Aurelius Omlin; Alexander Müller; Thomas Zilli; Hubert John; Helmut Kranzbuehler; Philipp A Kaufmann; Gustav K von Schulthess; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-28       Impact factor: 9.236

9.  68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Authors:  Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Andrea Farolfi; Cristina Fonti; Filippo Lodi; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-22       Impact factor: 9.236

10.  68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Authors:  Andrea Farolfi; Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Giambattista Siepe; Alessandro Lambertini; Riccardo Schiavina; Filippo Lodi; Alessio G Morganti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-15       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.